ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

OUTER CARTON

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

HorStem suspension for injection for horses

2. STATEMENT OF ACTIVE SUBSTANCES

Each vial contains:
$15x10^6$ /ml Equine umbilical cord mesenchymal stem cells

3. PHARMACEUTICAL FORM

Suspension for injection

4. PACKAGE SIZE

One 1 ml vial.

5. TARGET SPECIES

Horses

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Swirl gently before use.

Read the package leaflet before use.

For intraarticular use. To be administered only by a veterinary surgeon

8. WITHDRAWAL PERIOD (S)

Withdrawal period(s): Zero days

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP: {day/month/year}

11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated.

Do not freeze.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTEMATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only.
To be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

EquiCord S.L.
103-D Loeches
Polígono Industrial Ventorro del Cano
Alcorcón
28925 Madrid
Spain

16. MARKETING AUTHORISATION NUMBER(S)

Vm 46422/5000

17. MANUFACTURER'S BATCH NUMBER

Lot: {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

VIAL

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

HorStem suspension for injection for horses

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

$15x10^6$ /ml Equine umbilical cord mesenchymal stem cells

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

1 ml

4. ROUTE(S) OF ADMINISTRATION

Intraarticular use

5. WITHDRAWAL PERIOD (S)

Withdrawal period(s): zero days

6. BATCH NUMBER

Lot: {number}

7. EXPIRY DATE

EXP: {day/month/year}

8. FOR ANIMAL TREATMENT ONLY

For animal treatment only.

B. PACKAGE LEAFLET

PACKAGE LEAFLET:
HorStem suspension for injection for horses

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OFTHE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCHRELEASE, IF DIFFERENT

EquiCord S.L.
103-D Loeches
Polígono Industrial Ventorro del Cano
Alcorcón
28925 Madrid
Spain

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

HorStem suspension for injection for horses

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each vial contains:

Active Substance: $15x10^6$ Equine umbilical cord mesenchymal stem cells

Excipient:
- Adenosine
- Dextran-40
- Lactobionic acid
- HEPES N-(2-hydroxyethyl) piperazine-N´-(2-ethanesulfonic acid)
- Sodium hydroxide
- L- Glutathione
- Potassium chloride
- Potassium bicarbonate
- Potassium phosphate
- Dextrose
- Sucrose
- Mannitol
- Calcium chloride
- Magnesium chloride
- Potassium hydroxide
- Sodium hydroxide
- Trolox (6-hydroxyl-2,5,7,8- tetramethylchroman-2-carboxylic acid)
- Water for injections

Suspension for injection.

Cloudy colourless

suspension.

4. INDICATION

Reduction of lameness associated with mild to moderate degenerative joint disease (osteoarthritis) inhorses.

5. CONTRAINDICATIONS

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. ADVERSE REACTIONS

Very common

Acute synovitis with an acute onset of severe lameness, joint effusion and pain on palpation wasreported 24 hours after administration of the veterinary medicinal product. Substantial improvement was shown in the next 48 hours and complete remission in the following two weeks. In case of severe inflammation, administration of symptomatic treatment with Non- Steroidal Anti-Inflammatory Drugs (NSAIDs) could be necessary.

Common

Moderate joint effusion with no associated lameness has been observed 24 hours after HorStemadministration. Complete remission was observed over the following two weeks without any symptomatic treatment.
An increase in mild lameness was observed 24 hours after HorStem administration. Completeremission was observed within 3 days, without any symptomatic treatment.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports)

If you notice any side effects, even those not already listed in this package leaflet or you think that themedicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Horses.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Route of administration:
Intraarticular use.

Dosage
A single intraarticular injection of 1 ml ($15x10^6$ equine umbilical cord mesenchymal stem cells) intothe affected joint.

Method of administration
The veterinary product must be administered intraarticularly, only by a veterinary surgeon, taking special precautions to ensure the sterility of the injection process. The product must be handled andinjected following sterile techniques and in a clean environment.

Swirl gently before use in order to ensure the contents are well mixed.

9. ADVICE ON CORRECT ADMINISTRATION

Do not apply simultaneously with other intraarticular veterinary medicinal products.

The product should only be administered by a veterinary surgeon.

Use a 20G needle.

Intraarticular placement should be confirmed by the appearance of synovial fluid in the hub of theneedle.

10. WITHDRAWAL PERIOD (S)

Zero days.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store and transport refrigerated (2 □C – 8 □C).

Do not freeze.

Do not use this veterinary medicinal product after the expiry date which is stated on the vial label.

12. SPECIAL WARNINGS

Special warnings for each target species:

The veterinary medicinal product was demonstrated to be efficacious in horses affected by osteoarthritis in the metacarpo-phalangeal joint, distal interphalangeal joint, and tarsometatarsal/ distalintertarsal joint. No efficacy data are available regarding the treatment of other joints.

No efficacy data are available regarding the treatment in more than one arthritic joint at the same time.

The onset of efficacy may be gradual. Efficacy data demonstrated an effect from 35 days aftertreatment.

Special precautions for use in animals:

Correct placement of the needle is crucial to avoid accidental injection into blood vessels and anassociated risk of thrombosis.

The safety of the veterinary medicinal product has only been investigated in horses at least two yearsold.

Special precautions to be taken by the person administering the veterinary medicinal product toanimals:

Care should be taken to avoid accidental self-injection. Wash hands after use.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet orthe label to the physician.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy andlactation.

Use only accordingly to the benefit/risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interactions

Do not administer simultaneously with any other intraarticular veterinary medicinal product.

Overdose (symptoms, emergency procedures, antidotes):

Intraarticular administration of a 2x dose ($30x10^6$/2ml) of HorStem to 4 years old and older healthyhorses led to lameness in 5/6 animals and to signs of

inflammation in all animals. In 5/6 horses, theadverse reactions were mild and resolved spontaneously within 28 days. One horse required symptomatic treatment (NSAID) and its lameness resolved by day 14.

A second administration of the product at the recommended dose to healthy young horses in the samejoint, 28 days after the first administration at the recommended dose, led to an increase in frequency and severity of inflammation related to the treated joint (8/8 horses) and to an increase in the severityof the lameness observed (3/8 horses; up to grade 4/5 according to the American Association of Equine Practitioners lameness scale (AAEP)) compared to the first treatment. In one case, symptomatic treatment (NSAID) was requiredAdverse reactions in the other horses resolved spontaneously within a maximum of 21 days; lameness lasted for up to three days.

Incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with anyother veterinary medicinal products.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTEMATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures shouldhelp to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

15. OTHER INFORMATION

Cyclic olefin vial closed with a bromobutyl rubber stopper and a flip off aluminium cap.
Pack size: Cardboard box with 1 vial containing 1 ml.



Approved: 31 December 2021